Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Accumulated Expenses (2019 - 2025)

Vivos Therapeutics' Accumulated Expenses history spans 7 years, with the latest figure at $1.8 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $1.8 million for Q4 2025, up 84.12% from a year ago — trailing twelve months through Dec 2025 was $1.8 million (up 84.12% YoY), and the annual figure for FY2025 was $1.8 million, up 84.12%.
  • Accumulated Expenses for Q4 2025 was $1.8 million at Vivos Therapeutics, down from $2.7 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $3.2 million in Q1 2022 to a low of $1.0 million in Q4 2024.
  • The 5-year median for Accumulated Expenses is $2.0 million (2023), against an average of $2.0 million.
  • The sharpest move saw Accumulated Expenses plummeted 58.92% in 2023, then soared 84.12% in 2025.
  • Year by year, Accumulated Expenses stood at $1.4 million in 2021, then decreased by 2.79% to $1.4 million in 2022, then surged by 71.87% to $2.3 million in 2023, then tumbled by 57.11% to $1.0 million in 2024, then soared by 84.12% to $1.8 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $1.8 million, $2.7 million, and $2.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.